Gut Health Research

Evidence-Based IBS-C Constipation Treatment: A 2026 Research Update Irritable Bowel Syndrome with constipation (IBS-C) is characterized by chronic abdom…

Rifaximin Efficacy of 83.3% Drives Treatment for IBS and SIBO Overlap A 2026 systematic review of 55 studies analyzed the comparative effectiveness of M…

The Molecular Blueprint of a Butyrate Producer Short-chain fatty acids (SCFAs) like butyrate are the cornerstone of gut health, fueling colon cells and …

A New Framework for IBS-C: Moving Beyond Symptom Control Irritable bowel syndrome with constipation affects millions, yet many find standard treatments …

Rifaximin Demonstrated Most Consistent Efficacy for IBS-D and SIBO in Systematic Review of 55 Studies A 2026 systematic review in World J Methodol analy…

Evidence-Based IBS-C Management: Natural Products and Meal Timing Irritable bowel syndrome with constipation is a complex disorder driven by gut-brain a…

Rifaximin Leads in IBS-D and SIBO Treatment with 16.7% Adverse Events A 2026 systematic review of 55 clinical studies confirms rifaximin as the most eff…

Breaking the Relapse Cycle: Prokinetics for SIBO Prevention Small Intestinal Bacterial Overgrowth is frustratingly recurrent

New IBS-C Treatment Management Focuses on Gut-Brain Axis Dysfunction Irritable bowel syndrome with constipation affects millions, marked by abdominal pa…

Rifaximin Shows 16.7% Adverse Event Rate in Largest SIBO-IBS Antibiotic Review A 2026 systematic review analyzed 55 studies to compare three common anti…

Irritable bowel syndrome with constipation presents a complex clinical challenge

Rifaximin Achieves Highest Efficacy for IBS-D and SIBO, According to 2026 Review Rifaximin demonstrated the most consistent efficacy against SIBO and IB…